We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report?
Read MoreHide Full Article
A month has gone by since the last earnings report for Acadia Pharmaceuticals (ACAD - Free Report) . Shares have lost about 11.1% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Acadia due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
How Have Estimates Been Moving Since Then?
It turns out, fresh estimates have trended downward during the past month.
The consensus estimate has shifted -62.99% due to these changes.
VGM Scores
Currently, Acadia has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with an F. However, the stock was allocated a grade of B on the value side, putting it in the top 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Acadia has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Acadia belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Halozyme Therapeutics (HALO - Free Report) , has gained 11.8% over the past month. More than a month has passed since the company reported results for the quarter ended December 2024.
Halozyme Therapeutics reported revenues of $298.01 million in the last reported quarter, representing a year-over-year change of +29.6%. EPS of $1.26 for the same period compares with $0.82 a year ago.
For the current quarter, Halozyme Therapeutics is expected to post earnings of $0.98 per share, indicating a change of +24.1% from the year-ago quarter. The Zacks Consensus Estimate has changed +1.3% over the last 30 days.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Halozyme Therapeutics. Also, the stock has a VGM Score of B.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report?
A month has gone by since the last earnings report for Acadia Pharmaceuticals (ACAD - Free Report) . Shares have lost about 11.1% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Acadia due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
How Have Estimates Been Moving Since Then?
It turns out, fresh estimates have trended downward during the past month.
The consensus estimate has shifted -62.99% due to these changes.
VGM Scores
Currently, Acadia has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with an F. However, the stock was allocated a grade of B on the value side, putting it in the top 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Acadia has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Acadia belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Halozyme Therapeutics (HALO - Free Report) , has gained 11.8% over the past month. More than a month has passed since the company reported results for the quarter ended December 2024.
Halozyme Therapeutics reported revenues of $298.01 million in the last reported quarter, representing a year-over-year change of +29.6%. EPS of $1.26 for the same period compares with $0.82 a year ago.
For the current quarter, Halozyme Therapeutics is expected to post earnings of $0.98 per share, indicating a change of +24.1% from the year-ago quarter. The Zacks Consensus Estimate has changed +1.3% over the last 30 days.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Halozyme Therapeutics. Also, the stock has a VGM Score of B.